Biotech Values

[nivasvs]

<<<Also interesting from Scher are the comments about CVAs. I didn't know that the large trials using taxotere (ascent, or the dn-101 trial) had no CVAs. I think he makes a good point that the CVAs in 01 and 02A may be related to the systematic processing of the leukapheresis product. In that sense, suggesting the CVAs in 01 and 02A are no big deal because they are no different than the placebo arm is, justifiably, a false comparison.>>>>

In the study DN-101, in placebo group, there were 2 deaths related to CVAs. However there were no deaths in the treatment arm related to CVAs.

http://meeting.jco.org/cgi/content/full/24/18_suppl/4505/T1

In another Phase 1 and Phase 2 studies with taxotere and Estramustine combo, there was 1 and 2 deaths related to the CVAs. (Page 2515, Table 4)

http://jco.ascopubs.org/cgi/reprint/19/9/2509.pdf

Perhaps these CVAs are more to do with age and disease than the particular treatment.